Publications
Publications

Publications (2010-2017)

  1. Masroori, P. Cherry, N. Merindol, J.-x. Li, C. Dufour, L. Poulain, M.B. Plourde, L. Berthoux. 2017. Gene Knockout Shows That PML (TRIM19) Does Not Restrict the Early Stages of HIV-1 Infection in Human Cell Lines. mSphere e00233-17.
  2. -É. Nepveu-Traversy, A. Demogines, T. Fricke, M.B. Plourde, K. Riopel, M. Veillette, F. Diaz-Griffero, S.L. Sawyer, L. Berthoux. 2016. A putative SUMO interacting motif in the B30.2/SPRY domain of rhesus macaque TRIM5α important for NF-κB/AP-1 signaling and HIV-1 restriction. Heliyon e00056.
  3. Masroori, N. Mérindol, L. Berthoux. 2016. The interferon-induced antiviral protein PML (TRIM19) promotes the restriction and transcriptional silencing of lentiviruses in a context-specific,isoform-specific fashion. Retrovirology 13:19.
  4. Pizzato, M. Neagu, T. Pertel, C. Firrito, S. Ziglio, M. Zufferey, L. Berthoux, J. Luban. 2015. Lv4 is a capsid-specific antiviral activity in human blood cells that restricts viruses of the SIVmac/SIVsm/HIV-2 lineage prior to integration. P.L.O.S. Path. 16(11).
  5. Jung, K. Urak, M. Veillette, M.E. Nepveu-Traversy, Q.T. Pham, S. Hamel, J.J. Rossi, L. Berthoux. 2015. Preclinical assessment of mutant human TRIM5α as an anti-HIV-1 transgene. Hum. Gene Ther. 26:664-71.
  6. Mérindol, L. Berthoux. 2015. Restriction factors in HIV-1 disease progression (review). Curr. HIV Res. 13:448-61.
  7. Pawlica, C. Dufour, L. Berthoux. 2015. Inhibition of microtubules and dynein rescues HIV-1 from owl monkey TRIMCyp-mediated restriction in a cellular context-specific fashion. J. Gen. Virol. 96:874-86.
  8. Pawlica, L. Berthoux. 2014. Cytoplasmic dynein promotes HIV-1 uncoating. Viruses. 6:4195-211.
  9. Pawlica, V. LeSage, N. Poccardi, M.J. Tremblay, A.J. Mouland, L. Berthoux. 2014. Functional evidence for the involvement of microtubules and dynein complexes in TRIM5α-mediated restriction of retroviruses. J. Virol. 88:5661-76.2.
  10. -É. Nepveu-Traversy, L. Berthoux. 2014. The conserved sumoylation consensus site in TRIM5α modulates its immune activation functions. Virus Res. 184:30-8.
  11. Veillette, K. Bichel, P. Pawlica, S. M.V. Freund, M. B. Plourde, Q. T. Pham, L. C. James, L. Berthoux. 2013. The V86M mutation in HIV-1 Capsid Confers Resistance to TRIM5α by Abrogation of Cyclophilin A-Dependent Restriction and Enhancement of Viral Nuclear Import. Retrovirology, 10:25.
  12. T. Pham, M. Veillette, A. Brandariz-Nuñez, P. Pawlica, C. Thibert-Lefebvre, N. Chandonnet, F. Diaz-Griffero, L. Berthoux. 2013. A Novel Aminoacid Determinant of HIV-1 Restriction in the TRIM5α Variable 1 Region Isolated in a Random Mutagenic Screen. Virus Res 173:306-14.
  13. B. Plourde, A. Morchid, L. Iranezereza, L. Berthoux. 2013. The Bcl-XL/Bcl-2 inhibitor BH3I-2’ affects the stability and subcellular localization of sumoylated proteins. Int J Biochem Cell B. 45:826-35.
  14. Malbec, Q.T. Pham, M.B. Plourde, A. Létourneau-Hogan, M.-E. Nepveu-Traversy, L. Berthoux. 2010. Murine Double Minute 2 as a modulator of retroviral restrictions mediated by TRIM5α. Virology 405:414-23.
  15. T. Pham, A. Bouchard, M.G. Grütter, L. Berthoux. 2010. Generation of human TRIM5α mutants with high HIV-1 restriction activity. Gene Ther. 17:859-71.
  16. -X. Yang, V. Guen, J. Richard, E.A. Cohen, L. Berthoux. 2010. Cell context-specific involvement of ATR in early stages of retroviral replication. Virology 396:272-9.